Tag: FDA Regulation ⋅ Page 1

Professor Lietzan speaks at The Federalist Society’s COVID-19 & the Law Conference

Professor Erika Lietzan spoke at The Federalist Society’s COVID-19 & the Law Conference, contributing to the panel Regulation or “Don’t Let a Good Crisis Go to Waste.” She focused on decisions by regulators to de-regulate during the crisis — decisions to exercise enforcement discretion, to waive paperwork requirements, and to remove otherwise applicable restrictions — including decisions made by FDA…

Professor Lietzan’s FDA Expertise Sought by National & International Media

Professor Erika Lietzan researches, writes, and teaches primarily in the areas of food and drug regulation, intellectual property, and administrative law. Some of her recent scholarship has focused on the nature and purpose of the new drug approval system, federal regulation of fecal microbiota transplantation, federal regulation of products derived from cannabis, the political economy of the Hatch-Waxman (generic drug)…

Professor Lietzan Presents at Symposium on Federal Regulation of Cannabis

Professor Erika Lietzan presented her most recently completed article at a symposium on federal regulation of cannabis. The symposium, hosted by the Food and Drug Law Institute, convened academics, scientists from the Food and Drug Administration, lawyers from private practice, and industry developing cannabis-based products, to consider the path forward for a federal regulatory regime. Professor Lietzan’s forthcoming article in the American…

Professor Lietzan Speaks About FDA Regulation of Direct-to-Consumer Genetic Testing

Professor Erika Lietzan spoke on March 16 at “Frontiers in Precision Medicine III: Will Personalized Medicine Improve Population Health?” –  a full day symposium hosted by the University of Utah S.J. Quinney School of Law, the Huntsman Cancer Institute at the University of Utah, and the School of Medicine at the University of Utah.  Professor Lietzan’s presentation focused on FDA…

Professor Lietzan Presents Research Examining Impact of Pharmaceutical Regulation

In December, Professor Erika Lietzan spoke at a pharmaceutical law conference hosted by the CREDIMI, a center for research relating to markets and international investment, at the school of law at the Université de Bourgogne in Dijon, France. She presented her research examining the impact of pharmaceutical regulation on effective patent life and discussed its implications for restoration of patent…